|
1
|
Valko M, Leibfritz D, Moncol J, Cronin MT,
Mazur M and Telser J: Free radicals and antioxidants in normal
physiological functions and human disease. Int J Biochem Cell Biol.
39:44–84. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Duracková Z: Some current insights into
oxidative stress. Physiol Res. 59:459–469. 2010.PubMed/NCBI
|
|
3
|
Xing M: Oxidative stress: A new risk
factor for thyroid cancer. Endocr Relat Cancer. 19:C7–C11. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dröge W: Free radicals in the
physiological control of cell function. Physiol Rev. 82:47–95.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Giorgio M, Trinei M, Migliaccio E and
Pelicci PG: Hydrogen peroxide: A metabolic by-product or a common
mediator of ageing signals? Nat Rev Mol Cell Biol. 8:722–728. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rhee SG, Bae YS, Lee SR and Kwon J:
Hydrogen peroxide: A key messenger that modulates protein
phosphorylation through cysteine oxidation. Sci STKE.
2000:pe12000.PubMed/NCBI
|
|
7
|
Cha MK, Kim HK and Kim IH:
Thioredoxin-linked ‘thiol peroxidase’ from periplasmic space of
Escherichia coli. J Biol Chem. 270:28635–28641. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhou Y, Wan XY, Wang HL, Yan ZY, Hou YD
and Jin DY: Bacterial scavengase p20 is structurally and
functionally related to peroxiredoxins. Biochem Biophys Res Commun.
233:848–852. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nogoceke E, Gommel DU, Kiess M, Kalisz HM
and Flohé L: A Unique cascade of oxidoreductases catalyses
trypanothione-mediated peroxide metabolism in Crithidia
fasciculata. Biol Chem. 378:827–836. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bryk R, Griffin P and Nathan C:
Peroxynitrite reductase activity of bacterial peroxiredoxins.
Nature. 407:211–215. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hillas PJ, del Alba FS, Oyarzabal J, Wilks
A and De Montellano PR Ortiz: The AhpC and AhpD antioxidant defense
system of Mycobacterium tuberculosis. J Biol Chem. 275:18801–18809.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Karplus PA: A primer on peroxiredoxin
biochemistry. Free Radic Biol Med. 80:183–190. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Winterbourn CC: Reconciling the chemistry
and biology of reactive oxygen species. Nat Chem Biol. 4:278–286.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kim K, Kim IH, Lee KY, Rhee SG and
Stadtman ER: The isolation and purification of a specific
‘protector’ protein which inhibits enzyme inactivation by a
thiol/Fe(III)/O2 mixed-function oxidation system. J Biol Chem.
263:4704–4711. 1988.PubMed/NCBI
|
|
15
|
Chae HZ, Robison K, Poole LB, Church G,
Storz G and Rhee SG: Cloning and sequencing of thiol-specific
antioxidant from mammalian brain: Alkyl hydroperoxide reductase and
thiol-specific antioxidant define a large family of antioxidant
enzymes. Proc Natl Acad Sci USA. 91:7017–7021. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Edgar RS, Green EW, Zhao Y, van Ooijen G,
Olmedo M, Qin X, Xu Y, Pan M, Valekunja UK, Feeney KA, et al:
Peroxiredoxins are conserved markers of circadian rhythms. Nature.
485:459–464. 2012.PubMed/NCBI
|
|
17
|
Nelson KJ, Knutson ST, Soito L, Klomsiri
C, Poole LB and Fetrow JS: Analysis of the peroxiredoxin family:
Using active-site structure and sequence information for global
classification and residue analysis. Proteins. 79:947–964. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Perkins A, Gretes MC, Nelson KJ, Poole LB
and Karplus PA: Mapping the active site helix-to-strand conversion
of CxxxxC peroxiredoxin Q enzymes. Biochemistry. 51:7638–7650.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hall A, Nelson K, Poole LB and Karplus PA:
Structure-based insights into the catalytic power and
conformational dexterity of peroxiredoxins. Antioxid Redox Signal.
15:795–815. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dammeyer P and Arnér ES: Human protein
atlas of redox systems-what can be learnt? Biochim Biophys Acta.
1810:111–138. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Rhee SG, Chae HZ and Kim K:
Peroxiredoxins: A historical overview and speculative preview of
novel mechanisms and emerging concepts in cell signaling. Free
Radic Biol Med. 38:1543–1552. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Seo MS, Kang SW, Kim K, Baines IC, Lee TH
and Rhee SG: Identification of a new type of mammalian
peroxiredoxin that forms an intramolecular disulfide as a reaction
intermediate. J Biol Chem. 275:20346–20354. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kang SW, Baines IC and Rhee SG:
Characterization of a mammalian peroxiredoxin that contains one
conserved cysteine. J Biol Chem. 273:6303–6311. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fujii J, Ikeda Y, Kurahashi T and Homma T:
Physiological and pathological views of peroxiredoxin 4. Free Radic
Biol Med. 83:373–379. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rhee SG, Kang SW, Chang TS, Jeong W and
Kim K: Peroxiredoxin, a novel family of peroxidases. IUBMB Life.
52:35–41. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hofmann B, Hecht HJ and Flohé L:
Peroxiredoxins. Biol Chem. 383:347–364. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Declercq JP, Evrard C, Clippe A, Stricht
DV, Bernard A and Knoops B: Crystal structure of human
peroxiredoxin 5, a novel type of mammalian peroxiredoxin at 1.5 A
resolution. J Mol Biol. 311:751–759. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Monteiro G, Horta BB, Pimenta DC, Augusto
O and Netto LE: Reduction of 1-Cys peroxiredoxins by ascorbate
changes the thiol-specific antioxidant paradigm, revealing another
function of vitamin C. Proc Natl Acad Sci USA. 104:4886–4891. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Karplus PA and Hall A: Structural survey
of the peroxiredoxins. Subcell Biochem. 44:41–60. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wood ZA, Poole LB, Hantgan RR and Karplus
PA: Dimers to Doughnuts: Redox-sensitive oligomerization of
2-cysteine peroxiredoxins. Biochemistry. 41:5493–5504. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Barranco-Medina S, Lázaro JJ and Dietz KJ:
The oligomeric conformation of peroxiredoxins links redox state to
function. FEBS Lett. 583:1809–1816. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Fujii J and Ikeda Y: Advances in our
understanding of peroxiredoxin, a multifunctional, mammalian redox
protein. Redox Rep. 7:123–130. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Pisoschi AM and Pop A: The role of
antioxidants in the chemistry of oxidative stress: A review. Eur J
Med Chem. 97:55–74. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Fulda S, Gorman AM, Hori O and Samali A:
Cellular stress responses: Cell survival and cell death. Int J Cell
Biol. 2010:2140742010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kamiguti AS, Serrander L, Lin K, Harris
RJ, Cawley JC, Allsup DJ, Slupsky JR, Krause KH and Zuzel M:
Expression and activity of NOX5 in the circulating malignant B
cells of hairy cell leukemia. J Immunol. 175:8424–8430. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tsao SM, Yin MC and Liu WH: Oxidant stress
and B vitamins status in patients with non-small cell lung cancer.
Nutr Cancer. 59:8–13. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Khandrika L, Kumar B, Koul S, Maroni P and
Koul HK: Oxidative stress in prostate cancer. Cancer Lett.
282:125–136. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Patel BP, Rawal UM, Dave TK, Rawal RM,
Shukla SN, Shah PM and Patel PS: Lipid peroxidation, total
antioxidant status, and total thiol levels predict overall survival
in patients with oral squamous cell carcinoma. Integr Cancer Ther.
6:365–372. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Szatrowski TP and Nathan CF: Production of
large amounts of hydrogen peroxide by human tumor cells. Cancer
Res. 51:794–798. 1991.PubMed/NCBI
|
|
40
|
Nishikawa M: Reactive oxygen species in
tumor metastasis. Cancer Lett. 266:53–59. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Clerkin JS, Naughton R, Quiney C and
Cotter TG: Mechanisms of ROS modulated cell survival during
carcinogenesis. Cancer Lett. 266:30–36. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Krstić J, Trivanović D, Mojsilović S and
Santibanez JF: Transforming Growth Factor-Beta and Oxidative Stress
Interplay: Implications in Tumorigenesis and cancer progression.
Oxid Med Cell Longev. 2015:6545942015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ushio-Fukai M and Nakamura Y: Reactive
oxygen species and angiogenesis: NADPH oxidase as target for cancer
therapy. Cancer Lett. 266:37–52. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Fiaschi T and Chiarugi P: Oxidative
stress, tumor microenvironment, and metabolic reprogramming: A
diabolic liaison. Int J Cell Biol. 2012:7628252012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Weinberg F and Chandel NS: Reactive oxygen
species-dependent signaling regulates cancer. Cell Mol Life Sci.
66:3663–3673. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Cairns RA, Harris IS and Mak TW:
Regulation of cancer cell metabolism. Nat Rev Cancer. 11:85–95.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Park MH, Jo M, Kim YR, Lee CK and Hong JT:
Roles of peroxiredoxins in cancer, neurodegenerative diseases and
inflammatory diseases. Pharmacol Ther. 163:1–23. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Taguchi K, Motohashi H and Yamamoto M:
Molecular mechanisms of the Keap1-Nrf2 pathway in stress response
and cancer evolution. Genes Cells. 16:123–140. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Kwee JK: A paradoxical chemoresistance and
tumor suppressive role of antioxidant in solid cancer cells: A
strange case of Dr. Jekyll and Mr. Hyde. Biomed Res Int.
2014:2098452014. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Neumann CA, Cao J and Manevich Y:
Peroxiredoxin 1 and its role in cell signaling. Cell Cycle.
8:4072–4078. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Kim YJ, Ahn JY, Liang P, Ip C, Zhang Y and
Park YM: Human prx1 gene is a target of Nrf2 and is up-regulated by
hypoxia/reoxygenation: Implication to tumor biology. Cancer Res.
67:546–554. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Thélie A, Papillier P, Pennetier S,
Perreau C, Traverso JM, Uzbekova S, Mermillod P, Joly C, Humblot P
and Dalbiès-Tran R: Differential regulation of abundance and
deadenylation of maternal transcripts during bovine oocyte
maturation in vitro and in vivo. BMC Dev Biol. 7:1252007.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Neumann CA, Krause DS, Carman CV, Das S,
Dubey DP, Abraham JL, Bronson RT, Fujiwara Y, Orkin SH and Van
Etten RA: Essential role for the peroxiredoxin Prdx1 in erythrocyte
antioxidant defence and tumour suppression. Nature. 424:561–565.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Egler RA, Fernandes E, Rothermund K,
Sereika S, de Souza-Pinto N, Jaruga P, Dizdaroglu M and Prochownik
EV: Regulation of reactive oxygen species, DNA damage, and c-Myc
function by peroxiredoxin 1. Oncogene. 24:8038–8050. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Cao J, Schulte J, Knight A, Leslie NR,
Zagozdzon A, Bronson R, Manevich Y, Beeson C and Neumann CA: Prdx1
inhibits tumorigenesis via regulating PTEN/AKT activity. EMBO J.
28:1505–1517. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
O'Leary PC, Terrile M, Bajor M, Gaj P,
Hennessy BT, Mills GB, Zagozdzon A, O'Connor DP, Brennan DJ, Connor
K, et al: Peroxiredoxin-1 protects estrogen receptor α from
oxidative stress-induced suppression and is a protein biomarker of
favorable prognosis in breast cancer. Breast Cancer Res.
16:R792014. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Park YH, Kim SU, Lee BK, Kim HS, Song IS,
Shin HJ, Han YH, Chang KT, Kim JM, Lee DS, et al: Prx I suppresses
K-ras-driven lung tumorigenesis by opposing redox-sensitive
ERK/cyclin D1 pathway. Antioxid Redox Signal. 19:482–496. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Godfrey R, Arora D, Bauer R, Stopp S,
Müller JP, Heinrich T, Böhmer SA, Dagnell M, Schnetzke U, Scholl S,
et al: Cell transformation by FLT3 ITD in acute myeloid leukemia
involves oxidative inactivation of the tumor suppressor
protein-tyrosine phosphatase DEP-1/PTPRJ. Blood. 119:4499–4511.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Kim JH, Bogner PN, Baek SH, Ramnath N,
Liang P, Kim HR, Andrews C and Park YM: Up-regulation of
peroxiredoxin 1 in lung cancer and its implication as a prognostic
and therapeutic target. Clin Cancer Res. 14:2326–2333. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Quan C, Cha EJ, Lee HL, Han KH, Lee KM and
Kim WJ: Enhanced expression of peroxiredoxin I and VI correlates
with development, recurrence and progression of human bladder
cancer. J Urol. 175:1512–1516. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Chung KH, Lee DH, Kim Y, Kim TH, Huh JH,
Chung SG, Lee S, Lee C, Ko JJ and An HJ: Proteomic identification
of overexpressed PRDX 1 and its clinical implications in ovarian
carcinoma. J Proteome Res. 9:451–457. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Ren P, Ye H, Dai L, Liu M, Liu X, Chai Y,
Shao Q, Li Y, Lei N, Peng B, et al: Peroxiredoxin 1 is a
tumor-associated antigen in esophageal squamous cell carcinoma.
Oncol Rep. 30:2297–2303. 2013.PubMed/NCBI
|
|
64
|
Zhou J, Shen W, He X, Qian J, Liu S and Yu
G: Overexpression of Prdx1 in hilar cholangiocarcinoma: A predictor
for recurrence and prognosis. Int J Clin Exp Pathol. 8:9863–9874.
2015.PubMed/NCBI
|
|
65
|
Sun YL, Cai JQ, Liu F, Bi XY, Zhou LP and
Zhao XH: Aberrant expression of peroxiredoxin 1 and its clinical
implications in liver cancer. World J Gastroenterol.
21:10840–10852. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Cai CY, Zhai LL, Wu Y and Tang ZG:
Expression and clinical value of peroxiredoxin-1 in patients with
pancreatic cancer. Eur J Surg Oncol. 41:228–235. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Kinnula VL, Lehtonen S, Sormunen R,
Kaarteenaho-Wiik R, Kang SW, Rhee SG and Soini Y: Overexpression of
peroxiredoxins I, II, III, V, and VI in malignant mesothelioma. J
Pathol. 196:316–323. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Svendsen A, Verhoeff JJ, Immervoll H,
Brøgger JC, Kmiecik J, Poli A, Netland IA, Prestegarden L,
Planagumà J, Torsvik A, et al: Expression of the progenitor marker
NG2/CSPG4 predicts poor survival and resistance to ionising
radiation in glioblastoma. Acta Neuropathol. 122:495–510. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Riddell JR, Maier P, Sass SN, Moser MT,
Foster BA and Gollnick SO: Peroxiredoxin 1 stimulates endothelial
cell expression of VEGF via TLR4 dependent activation of HIF-1α.
PLoS One. 7:e503942012. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Jiang H, Wu L, Mishra M, Chawsheen HA and
Wei Q: Expression of peroxiredoxin 1 and 4 promotes human lung
cancer malignancy. Am J Cancer Res. 4:445–460. 2014.PubMed/NCBI
|
|
71
|
Ha B, Kim EK, Kim JH, Lee HN, Lee KO, Lee
SY and Jang HH: Human peroxiredoxin 1 modulates TGF-β1-induced
epithelial-mesenchymal transition through its peroxidase activity.
Biochem Biophys Res Commun. 421:33–37. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Du ZX, Yan Y, Zhang HY, Liu BQ, Gao YY,
Niu XF, Guan Y, Meng X and Wang HQ: Suppression of MG132-mediated
cell death by peroxiredoxin 1 through influence on ASK1 activation
in human thyroid cancer cells. Endocr Relat Cancer. 17:553–560.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Song IS, Kim SU, Oh NS, Kim J, Yu DY,
Huang SM, Kim JM, Lee DS and Kim NS: Peroxiredoxin I contributes to
TRAIL resistance through suppression of redox-sensitive caspase
activation in human hepatoma cells. Carcinogenesis. 30:1106–1114.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Yanagawa T, Ishikawa T, Ishii T, Tabuchi
K, Iwasa S, Bannai S, Omura K, Suzuki H and Yoshida H:
Peroxiredoxin I expression in human thyroid tumors. Cancer Lett.
145:127–132. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Nicolussi A, D'Inzeo S, Mincione G,
Buffone A, Di Marcantonio MC, Cotellese R, Cichella A, Capalbo C,
Di Gioia C, Nardi F, et al: PRDX1 and PRDX6 are repressed in
papillary thyroid carcinomas via BRAF V600E-dependent and
-independent mechanisms. Int J Oncol. 44:548–556. 2014.PubMed/NCBI
|
|
76
|
Wood ZA, Poole LB and Karplus PA:
Peroxiredoxin evolution and the regulation of hydrogen peroxide
signaling. Science. 300:650–653. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
O'Neill JS and Reddy AB: Circadian clocks
in human red blood cells. Nature. 469:498–503. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Cho CS, Yoon HJ, Kim JY, Woo HA and Rhee
SG: Circadian rhythm of hyperoxidized peroxiredoxin II is
determined by hemoglobin autoxidation and the 20S proteasome in red
blood cells. Proc Natl Acad Sci USA. 111:12043–12048. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Avitabile D, Ranieri D, Nicolussi A,
D'Inzeo S, Capriotti AL, Genovese L, Proietti S, Cucina A, Coppa A,
Samperi R, et al: Peroxiredoxin 2 nuclear levels are regulated by
circadian clock synchronization in human keratinocytes. Int J
Biochem Cell Biol. 53:24–34. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Sobotta MC, Liou W, Stöcker S, Talwar D,
Oehler M, Ruppert T, Scharf AN and Dick TP: Peroxiredoxin-2 and
STAT3 form a redox relay for H2O2 signaling. Nat Chem Biol.
11:64–70. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Rhee SG and Woo HA: Multiple functions of
peroxiredoxins: Peroxidases, sensors and regulators of the
intracellular messenger H2O2, and protein
chaperones. Antioxid Redox Signal. 15:781–794. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Huo YY, Li G, Duan RF, Gou Q, Fu CL, Hu
YC, Song BQ, Yang ZH, Wu DC and Zhou PK: PTEN deletion leads to
deregulation of antioxidants and increased oxidative damage in
mouse embryonic fibroblasts. Free Radic Biol Med. 44:1578–1591.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Barbosa AC, Funato N, Chapman S, McKee MD,
Richardson JA, Olson EN and Yanagisawa H: Hand transcription
factors cooperatively regulate development of the distal midline
mesenchyme. Dev Biol. 310:154–168. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Furuta J, Nobeyama Y, Umebayashi Y, Otsuka
F, Kikuchi K and Ushijima T: Silencing of Peroxiredoxin 2 and
aberrant methylation of 33 CpG islands in putative promoter regions
in human malignant melanomas. Cancer Res. 66:6080–6086. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Lee DJ, Kang DH, Choi M, Choi YJ, Lee JY,
Park JH, Park YJ, Lee KW and Kang SW: Peroxiredoxin-2 represses
melanoma metastasis by increasing E-Cadherin/β-Catenin complexes in
adherens junctions. Cancer Res. 73:4744–4757. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Feng J, Fu Z, Guo J, Lu W, Wen K, Chen W,
Wang H, Wei J and Zhang S: Overexpression of peroxiredoxin 2
inhibits TGF-β1-induced epithelial-mesenchymal transition and cell
migration in colorectal cancer. Mol Med Rep. 10:867–873.
2014.PubMed/NCBI
|
|
87
|
Pylväs M, Puistola U, Kauppila S, Soini Y
and Karihtala P: Oxidative stress-induced antioxidant enzyme
expression is an early phenomenon in ovarian carcinogenesis. Eur J
Cancer. 46:1661–1667. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Hellman K, Alaiya AA, Becker S, Lomnytska
M, Schedvins K, Steinberg W, Hellström AC, Andersson S, Hellman U
and Auer G: Differential tissue-specific protein markers of vaginal
carcinoma. Br J Cancer. 100:1303–1314. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Kim K, Yu M, Han S, Oh I, Choi YJ, Kim S,
Yoon K, Jung M and Choe W: Expression of human peroxiredoxin
isoforms in response to cervical carcinogenesis. Oncol Rep.
21:1391–1396. 2009.PubMed/NCBI
|
|
90
|
Basu A, Banerjee H, Rojas H, Martinez SR,
Roy S, Jia Z, Lilly MB, De León M and Casiano CA: Differential
expression of peroxiredoxins in prostate cancer: Consistent
upregulation of PRDX3 and PRDX4. Prostate. 71:755–765. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Zhang B, Wang K, He G, Guan X, Liu B, Liu
Y and Bai Y: Polymorphisms of peroxiredoxin 1, 2 and 6 are not
associated with esophageal cancer. J Cancer Res Clin Oncol.
138:621–626. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Trzeciecka A, Klossowski S, Bajor M,
Zagozdzon R, Gaj P, Muchowicz A, Malinowska A, Czerwoniec A,
Barankiewicz J, Domagala A, et al: Dimeric peroxiredoxins are
druggable targets in human Burkitt lymphoma. Oncotarget.
7:1717–1731. 2016.PubMed/NCBI
|
|
93
|
Stresing V, Baltziskueta E, Rubio N,
Blanco J, Arriba MC, Valls J, Janier M, Clézardin P, Sanz-Pamplona
R, Nieva C, et al: Peroxiredoxin 2 specifically regulates the
oxidative and metabolic stress response of human metastatic breast
cancer cells in lungs. Oncogene. 32:724–735. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Lu W, Fu Z, Wang H, Feng J, Wei J and Guo
J: Peroxiredoxin 2 is upregulated in colorectal cancer and
contributes to colorectal cancer cells' survival by protecting
cells from oxidative stress. Mol Cell Biochem. 387:261–270. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Watabe S, Hiroi T, Yamamoto Y, Fujioka Y,
Hasegawa H, Yago N and Takahashi SY: SP-22 is a
thioredoxin-dependent peroxide reductase in mitochondria. Eur J
Biochem. 249:52–60. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Miranda-Vizuete A, Damdimopoulos AE and
Spyrou G: The mitochondrial thioredoxin system. Antioxid Redox
Signal. 2:801–810. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Olmos Y, Sánchez-Gómez FJ, Wild B,
García-Quintans N, Cabezudo S, Lamas S and Monsalve M: SirT1
regulation of antioxidant genes is dependent on the formation of a
FoxO3a/PGC-1α complex. Antioxid Redox Signal. 19:1507–1521. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Song IS, Jeong YJ, Jeong SH, Heo HJ, Kim
HK, Bae KB, Park YH, Kim SU, Kim JM, Kim N, et al: FOXM1-Induced
PRX3 regulates stemness and survival of colon cancer cells via
maintenance of mitochondrial function. Gastroenterology.
149:1006–1016.e9. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Li KK, Pang JC, Lau KM, Zhou L, Mao Y,
Wang Y, Poon WS and Ng HK: MiR-383 is downregulated in
medulloblastoma and targets peroxiredoxin 3 (PRDX3). Brain Pathol.
23:413–425. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
He HC, Zhu JG, Chen XB, Chen SM, Han ZD,
Dai QS, Ling XH, Fu X, Lin ZY, Deng YH, et al: MicroRNA-23b
downregulates peroxiredoxin III in human prostate cancer. FEBS
Lett. 586:2451–2458. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Xi H, Gao YH, Han DY, Li QY, Feng LJ,
Zhang W, Ji G, Xiao JC, Zhang HZ and Wei Q: Hypoxia inducible
factor-1α suppresses Peroxiredoxin 3 expression to promote
proliferation of CCRCC cells. FEBS Lett. 588:3390–3394. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Choi JH, Kim TN, Kim S, Baek SH, Kim JH,
Lee SR and Kim JR: Overexpression of mitochondrial thioredoxin
reductase and peroxiredoxin III in hepatocellular carcinomas.
Anticancer Res. 22:3331–3335. 2002.PubMed/NCBI
|
|
103
|
Karihtala P, Mäntyniemi A, Kang SW,
Kinnula VL and Soini Y: Peroxiredoxins in breast carcinoma. Clin
Cancer Res. 9:3418–3424. 2003.PubMed/NCBI
|
|
104
|
Ummanni R, Barreto F, Venz S, Scharf C,
Barett C, Mannsperger HA, Brase JC, Kuner R, Schlomm T, Sauter G,
et al: Peroxiredoxins 3 and 4 are overexpressed in prostate cancer
tissue and affect the proliferation of prostate cancer cells in
vitro. J Proteome Res. 11:2452–2466. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Kim YS, Lee HL, Lee KB, Park JH, Chung WY,
Lee KS, Sheen SS, Park KJ and Hwang SC: Nuclear factor E2-related
factor 2 dependent overexpression of sulfiredoxin and peroxiredoxin
III in human lung cancer. Korean J Intern Med. 26:304–313. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Hu JX, Gao Q and Li L: Peroxiredoxin 3 is
a novel marker for cell proliferation in cervical cancer. Biomed
Rep. 1:228–230. 2013.PubMed/NCBI
|
|
107
|
Schulte J: Peroxiredoxin 4: A
multifunctional biomarker worthy of further exploration. BMC Med.
9:1372011. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Okado-Matsumoto A, Matsumoto A, Fujii J
and Taniguchi N: Peroxiredoxin IV is a secretable protein with
heparin-binding properties under reduced conditions. J Biochem.
127:493–501. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Roumes H, Pires-Alves A, Gonthier-Maurin
L, Dargelos E and Cottin P: Investigation of peroxiredoxin IV as a
calpain-regulated pathway in cancer. Anticancer Res. 30:5085–5089.
2010.PubMed/NCBI
|
|
110
|
Ikeda Y, Nakano M, Ihara H, Ito R,
Taniguchi N and Fujii J: Different consequences of reactions with
hydrogen peroxide and t-butyl hydroperoxide in the hyperoxidative
inactivation of rat peroxiredoxin-4. J Biochem. 149:443–453. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Zhu L, Yang K, Wang X, Wang X and Wang CC:
A novel reaction of peroxiredoxin 4 towards substrates in oxidative
protein folding. PLoS One. 9:e1055292014. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Ishii T, Warabi E and Yanagawa T: Novel
roles of peroxiredoxins in inflammation, cancer and innate
immunity. J Clin Biochem Nutr. 50:91–105. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Mishra M, Jiang H, Wu L, Chawsheen HA and
Wei Q: The sulfiredoxin-peroxiredoxin (Srx-Prx) axis in cell signal
transduction and cancer development. Cancer Lett. 366:150–159.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Chen JH, Ni RZ, Xiao MB, Guo JG and Zhou
JW: Comparative proteomic analysis of differentially expressed
proteins in human pancreatic cancer tissue. Hepatobiliary Pancreat
Dis Int. 8:193–200. 2009.PubMed/NCBI
|
|
115
|
Pritchard C, Mecham B, Dumpit R, Coleman
I, Bhattacharjee M, Chen Q, Sikes RA and Nelson PS: Conserved gene
expression programs integrate mammalian prostate development and
tumorigenesis. Cancer Res. 69:1739–1747. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Chang KP, Yu JS, Chien KY, Lee CW, Liang
Y, Liao CT, Yen TC, Lee LY, Huang LL, Liu SC, et al: Identification
of PRDX4 and P4HA2 as metastasis-associated proteins in oral cavity
squamous cell carcinoma by comparative tissue proteomics of
microdissected specimens using iTRAQ technology. J Proteome Res.
10:4935–4947. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Karihtala P, Kauppila S, Soini Y and
Arja-Jukkola-Vuorinen: Oxidative stress and counteracting
mechanisms in hormone receptor positive, triple-negative and
basal-like breast carcinomas. BMC Cancer. 11:2622011. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Karihtala P, Soini Y, Vaskivuo L, Bloigu R
and Puistola U: DNA adduct 8-hydroxydeoxyguanosine, a novel
putative marker of prognostic significance in ovarian carcinoma.
Int J Gynecol Cancer. 19:1047–1051. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Yi N, Xiao MB, Ni WK, Jiang F, Lu CH and
Ni RZ: High expression of peroxiredoxin 4 affects the survival time
of colorectal cancer patients, but is not an independent
unfavorable prognostic factor. Mol Clin Oncol. 2:767–772.
2014.PubMed/NCBI
|
|
120
|
Wei Q, Jiang H, Xiao Z, Baker A, Young MR,
Veenstra TD and Colburn NH: Sulfiredoxin-Peroxiredoxin IV axis
promotes human lung cancer progression through modulation of
specific phosphokinase signaling. Proc Natl Acad Sci USA.
108:7004–7009. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Palande KK, Beekman R, van der Meeren LE,
Beverloo HB, Valk PJ and Touw IP: The antioxidant protein
peroxiredoxin 4 is epigenetically down regulated in acute
promyelocytic leukemia. PLoS One. 6:e163402011. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Knoops B, Goemaere J, Van der Eecken V and
Declercq JP: Peroxiredoxin 5: Structure, mechanism, and function of
the mammalian atypical 2-Cys peroxiredoxin. Antioxid Redox Signal.
15:817–829. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Nguyên-Nhu NT, Berck J, Clippe A,
Duconseille E, Cherif H, Boone C, Van der Eecken V, Bernard A,
Banmeyer I and Knoops B: Human peroxiredoxin 5 gene organization,
initial characterization of its promoter and identification of
alternative forms of mRNA. Biochim Biophys Acta. 1769:472–483.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Graves JA, Metukuri M, Scott D, Rothermund
K and Prochownik EV: Regulation of reactive oxygen species
homeostasis by peroxiredoxins and c-Myc. J Biol Chem.
284:6520–6529. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Kropotov A, Usmanova N, Serikov V,
Zhivotovsky B and Tomilin N: Mitochondrial targeting of human
peroxiredoxin V protein and regulation of PRDX5 gene expression by
nuclear transcription factors controlling biogenesis of
mitochondria. FEBS J. 274:5804–5814. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Shiota M, Izumi H, Miyamoto N, Onitsuka T,
Kashiwagi E, Kidani A, Hirano G, Takahashi M, Ono M, Kuwano M, et
al: Ets regulates peroxiredoxin1 and 5 expressions through their
interaction with the high-mobility group protein B1. Cancer Sci.
99:1950–1959. 2008.PubMed/NCBI
|
|
127
|
Bur H, Haapasaari KM, Turpeenniemi-Hujanen
T, Kuittinen O, Auvinen P, Marin K, Koivunen P, Sormunen R, Soini Y
and Karihtala P: Oxidative stress markers and mitochondrial
antioxidant enzyme expression are increased in aggressive Hodgkin
lymphomas. Histopathology. 65:319–327. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Gérard AC, Many MC, Daumerie Ch, Knoops B
and Colin IM: Peroxiredoxin 5 expression in the human thyroid
gland. Thyroid. 15:205–209. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Fernandez-Ranvier GG, Weng J, Yeh RF,
Shibru D, Khafnashar E, Chung KW, Hwang J, Duh QY, Clark OH and
Kebebew E: Candidate diagnostic markers and tumor suppressor genes
for adrenocortical carcinoma by expression profile of genes on
chromosome 11q13. World J Surg. 32:873–881. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Fisher AB: Peroxiredoxin 6: A bifunctional
enzyme with glutathione peroxidase and phospholipase A2
activities. Antioxid Redox Signal. 15:831–844. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Choi HJ, Kang SW, Yang CH, Rhee SG and Ryu
SE: Crystal structure of a novel human peroxidase enzyme at 2.0 A
resolution. Nat Struct Biol. 5:400–406. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Chowdhury I, Fisher AB,
Christofidou-Solomidou M, Gao L, Tao JQ, Sorokina EM, Lien YC,
Bates SR and Feinstein SI: Keratinocyte growth factor and
glucocorticoid induction of human peroxiredoxin 6 gene expression
occur by independent mechanisms that are synergistic. Antioxid
Redox Signal. 20:391–402. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Chowdhury I, Mo Y, Gao L, Kazi A, Fisher
AB and Feinstein SI: Oxidant stress stimulates expression of the
human peroxiredoxin 6 gene by a transcriptional mechanism involving
an antioxidant response element. Free Radic Biol Med. 46:146–153.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Fatma N, Kubo E, Takamura Y, Ishihara K,
Garcia C, Beebe DC and Singh DP: Loss of NF-kappaB control and
repression of Prdx6 gene transcription by reactive oxygen
species-driven SMAD3-mediated transforming growth factor beta
signaling. J Biol Chem. 284:22758–22772. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Chhunchha B, Fatma N, Bhargavan B, Kubo E,
Kumar A and Singh DP: Specificity protein, Sp1-mediated increased
expression of Prdx6 as a curcumin-induced antioxidant defense in
lens epithelial cells against oxidative stress. Cell Death Dis.
2:e2342011. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Wu X, Ji P, Zhang L, Bu G, Gu H, Wang X,
Xiong Y and Zuo B: The expression of porcine Prdx6 gene is
up-regulated by C/EBPβ and CREB. PLoS One. 10:e01448512015.
View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Power JH, Asad S, Chataway TK, Chegini F,
Manavis J, Temlett JA, Jensen PH, Blumbergs PC and Gai WP:
Peroxiredoxin 6 in human brain: Molecular forms, cellular
distribution, and association with Alzheimer's disease pathology.
Acta Neuropathol. 115:611–622. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Yun HM, Choi DY, Oh KW and Hong JT: PRDX6
exacerbates dopaminergic neurodegeneration in a MPTP mouse model of
Parkinson's disease. Mol Neurobiol. 52:422–431. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
El Eter E, Al Masri A, Habib S, Al Zamil
H, Al Hersi A, Al Hussein F and Al Omran M: Novel links among
peroxiredoxins, endothelial dysfunction, and severity of
atherosclerosis in type 2 diabetic patients with peripheral
atherosclerotic disease. Cell Stress Chaperones. 19:173–181. 2014.
View Article : Google Scholar
|
|
140
|
Kubo E, Fatma N, Akagi Y, Beier DR, Singh
SP and Singh DP: TAT-mediated PRDX6 protein transduction protects
against eye lens epithelial cell death and delays lens opacity. Am
J Physiol Cell Physiol. 294:C842–C855. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Thongwatchara P, Promwikorn W, Srisomsap
C, Chokchaichamnankit D, Boonyaphiphat P and Thongsuksai P:
Differential protein expression in primary breast cancer and
matched axillary node metastasis. Oncol Rep. 26:185–191.
2011.PubMed/NCBI
|
|
142
|
Zhang J, Wang K, Zhang J, Liu SS, Dai L
and Zhang JY: Using proteomic approach to identify tumor-associated
proteins as biomarkers in human esophageal squamous cell carcinoma.
J Proteome Res. 10:2863–2872. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Schremmer B, Manevich Y, Feinstein SI and
Fisher AB: Peroxiredoxins in the lung with emphasis on
peroxiredoxin VI. Subcell Biochem. 44:317–344. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Park JY, Kim SA, Chung JW, Bang S, Park
SW, Paik YK and Song SY: Proteomic analysis of pancreatic juice for
the identification of biomarkers of pancreatic cancer. J Cancer Res
Clin Oncol. 137:1229–1238. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Shukla S, Pranay A, D'Cruz AK, Chaturvedi
P, Kane SV and Zingde SM: Immunoproteomics reveals that cancer of
the tongue and the gingivobuccal complex exhibit differential
autoantibody response. Cancer Biomark. 5:127–135. 2009.PubMed/NCBI
|
|
146
|
Kuusisto ME, Haapasaari KM,
Turpeenniemi-Hujanen T, Jantunen E, Soini Y, Peroja P, Bloigu R,
Karihtala P and Kuittinen O: High intensity of cytoplasmic
peroxiredoxin VI expression is associated with adverse outcome in
diffuse large B-cell lymphoma independently of international
prognostic index. J Clin Pathol. 68:552–556. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Chang XZ, Li DQ, Hou YF, Wu J, Lu JS, Di
GH, Jin W, Ou ZL, Shen ZZ and Shao ZM: Identification of the
functional role of peroxiredoxin 6 in the progression of breast
cancer. Breast Cancer Res. 9:R762007. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Raatikainen S, Aaaltomaa S, Kärjä V and
Soini Y: Increased peroxiredoxin 6 expression predicts biochemical
recurrence in prostate cancer patients after radical prostatectomy.
Anticancer Res. 35:6465–6470. 2015.PubMed/NCBI
|
|
149
|
Sofiadis A, Becker S, Hellman U,
Hultin-Rosenberg L, Dinets A, Hulchiy M, Zedenius J, Wallin G,
Foukakis T, Höög A, et al: Proteomic profiling of follicular and
papillary thyroid tumors. Eur J Endocrinol. 166:657–667. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Ho JN, Lee SB, Lee SS, Yoon SH, Kang GY,
Hwang SG and Um HD: Phospholipase A2 activity of peroxiredoxin 6
promotes invasion and metastasis of lung cancer cells. Mol Cancer
Ther. 9:825–832. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Seibold P, Hall P, Schoof N, Nevanlinna H,
Heikkinen T, Benner A, Liu J, Schmezer P, Popanda O, Flesch-Janys D
and Chang-Claude J: Polymorphisms in oxidative stress-related genes
and mortality in breast cancer patients-potential differential
effects by radiotherapy? Breast. 22:817–823. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Glasauer A and Chandel NS: Targeting
antioxidants for cancer therapy. Biochem Pharmacol. 92:90–101.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Gorrini C, Harris IS and Mak TW:
Modulation of oxidative stress as an anticancer strategy. Nat Rev
Drug Discov. 12:931–947. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Yang Y, Karakhanova S, Werner J and Bazhin
AV: Reactive oxygen species in cancer biology and anticancer
therapy. Curr Med Chem. 20:3677–3692. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Wang T, Diaz AJ and Yen Y: The role of
peroxiredoxin II in chemoresistance of breast cancer cells. Breast
Cancer (Dove Med Press). 6:73–80. 2014.PubMed/NCBI
|
|
156
|
Chung YM, Yoo YD, Park JK, Kim YT and Kim
HJ: Increased expression of peroxiredoxin II confers resistance to
cisplatin. Anticancer Res. 21:1129–1133. 2001.PubMed/NCBI
|
|
157
|
Kalinina EV, Berezov TT, Shtil AA, Chernov
NN, Glazunova VA, Novichkova MD and Nurmuradov NK: Expression of
peroxiredoxin 1, 2, 3, and 6 genes in cancer cells during drug
resistance formation. Bull Exp Biol Med. 153:878–881. 2012.(In
English, Russian). View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Park SH, Chung YM, Lee YS, Kim HJ, Kim JS,
Chae HZ and Yoo YD: Antisense of human peroxiredoxin II enhances
radiation-induced cell death. Clin Cancer Res. 6:4915–4920.
2000.PubMed/NCBI
|
|
159
|
Pak JH, Choi WH, Lee HM, Joo WD, Kim JH,
Kim YT, Kim YM and Nam JH: Peroxiredoxin 6 overexpression
attenuates cisplatin-induced apoptosis in human ovarian cancer
cells. Cancer Invest. 29:21–28. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Kwon T, Rho JK, Lee JC, Park YH, Shin HJ,
Cho S, Kang YK, Kim BY, Yoon DY and Yu DY: An important role for
peroxiredoxin II in survival of A549 lung cancer cells resistant to
gefitinib. Exp Mol Med. 47:e1652015. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
McDonald C, Muhlbauer J, Perlmutter G,
Taparra K and Phelan SA: Peroxiredoxin proteins protect MCF-7
breast cancer cells from doxorubicin-induced toxicity. Int J Oncol.
45:219–226. 2014.PubMed/NCBI
|
|
162
|
Song IS, Kim HK, Jeong SH, Lee SR, Kim N,
Rhee BD, Ko KS and Han J: Mitochondrial peroxiredoxin III is a
potential target for cancer therapy. Int J Mol Sci. 12:7163–7185.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Li L and Yu AQ: The functional role of
peroxiredoxin 3 in reactive oxygen species, apoptosis, and
chemoresistance of cancer cells. J Cancer Res Clin Oncol.
141:2071–2077. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Kropotov A, Gogvadze V, Shupliakov O,
Tomilin N, Serikov VB, Tomilin NV and Zhivotovsky B: Peroxiredoxin
V is essential for protection against apoptosis in human lung
carcinoma cells. Exp Cell Res. 312:2806–2815. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Butterfield LH, Merino A, Golub SH and
Shau H: From cytoprotection to tumor suppression: The
multifactorial role of peroxiredoxins. Antioxid Redox Signal.
1:385–402. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Neumann CA and Fang Q: Are peroxiredoxins
tumor suppressors? Curr Opin Pharmacol. 7:375–380. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Woo HA, Jeong W, Chang TS, Park KJ, Park
SJ, Yang JS and Rhee SG: Reduction of cysteine sulfinic acid by
sulfiredoxin is specific to 2-cys peroxiredoxins. J Biol Chem.
280:3125–3128. 2005. View Article : Google Scholar : PubMed/NCBI
|
